VolitionRx vs Xenetic Biosciences
VNRX and XBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How VNRX and XBIO compare
Xenetic Biosciences is the larger company, worth 1.5 times as much as VolitionRx ($3.8M against $2.6M).
VolitionRx grew revenue faster over the last twelve months (86.3% versus 33.3% for Xenetic Biosciences).
Xenetic Biosciences keeps more of each dollar of sales as profit, with a net margin of −75.9% compared with −1043% at VolitionRx.
Xenetic Biosciences scores higher on the StockData Score (12 against 4 for VolitionRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | VNRX | XBIO |
|---|---|---|
| Size and price | ||
| Market cap | $2.6M | $3.8M |
| Share price | $0.189 | $1.61 |
| Change, 1 year | −97.2% | −38.1% |
| Change, 5 years | −99.7% | −88.9% |
| Beta (5Y) | 2.26 | 1.14 |
| Employees | 75 | 2 |
| StockData Score | ||
| Total score | 4 | 12 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 2 | 2 |
| Performance score | 1 | 2 (better) |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.0× (better) | 1.2× |
| P/B | – | 0.6× |
| FCF yield | −760% | – |
| Fair value | – | $4.53 |
| Margin of safety | – | 64.4% |
| Growth | ||
| Revenue growth (TTM) | 86.3% (better) | 33.3% |
| Revenue growth, 5Y average | 164% (better) | 46.8% |
| Profitability | ||
| Operating margin | −790% | −81.0% (better) |
| Net margin | −1043% | −75.9% (better) |
| FCF margin | −797% | – |
| Return on equity | – | −47.0% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 0.30 | 7.43 (better) |
| Altman Z-score | −53.84 | −37.70 (better) |
| Piotroski F-score | 2 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | −751% | – |
| Shareholder yield | −751% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 14.1% | 6.5% |
| Held by insiders | – | 12.2% |
| Insider net buying, 12 months | $0 | – |
| Short interest, % of float | – | 1.8% |
Go deeper
- VNRX stock overview
- VNRX income statement
- VNRX valuation and score
- XBIO stock overview
- XBIO income statement
- XBIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.